Treating AIDS-associated cerebral toxoplasmosis - pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids.
We conducted a retrospective study of AIDS-associated cerebral toxoplasmosis. Eighteen patients received pyrimethamine plus sulfadiazine and 25 co-trimoxazole, with comparable baseline characteristics. There were no differences in clinical outcomes, but co-trimoxazole was better tolerated (p = 0.066). There was also a trend towards more deaths among patients who received glucocorticoids.
Arens
James
J
Division of Clinical Pharmacology, University of Cape Town.
Barnes
Karen
K
Crowley
Nicola
N
Maartens
Gary
G
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D011739:Pyrimethamine / Q000627:therapeutic use; D012189:Retrospective Studies; D013019:South Africa / Q000453:epidemiology; D013411:Sulfadiazine / Q000627:therapeutic use; D016781:Toxoplasmosis, Cerebral / Q000188:drug therapy* / Q000401:mortality; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000981:Antiprotozoal Agents; D005938:Glucocorticoids; D013411:Sulfadiazine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D011739:Pyrimethamine